Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 5, 2017
Event: Entry into a Material Definitive Agreement to sell the DaVita Medical Group (DMG) division.
Key Financial Metrics and Transaction Details
- Transaction Value: $4,900,000,000 in cash (Purchase Price).
- Asset Sold: All issued and outstanding equity interests of DaVita Medical Holdings, LLC (DMH), comprising the DMG division.
- Buyer: Collaborative Care Holdings, LLC, a wholly owned subsidiary of Optum, Inc. (UnitedHealth Group).
- Financing: Buyer expects to finance the purchase with cash on hand; no financing contingency included.
- Use of Proceeds: Significant stock repurchases over one to two years, debt repayment, and general corporate purposes.
- Other Metrics: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the company or the division.
Material Changes and Agreements
The filing announces a definitive agreement to divest a major business segment. Key contractual terms include:
- Non-Competition: DaVita is prohibited from engaging in a business competing with DMG in the U.S. for three years post-closing.
- Non-Solicitation: DaVita is prohibited from soliciting or hiring certain DMG employees for two years post-closing.
- Exclusivity: DaVita agreed not to solicit or encourage competing proposals for the DMG business.
Guidance, Outlook, and Risks
- Closing Timeline: Expected to close in 2018, subject to regulatory approvals and customary conditions.
- Termination Rights: The agreement may be terminated if closing does not occur by June 4, 2018 (subject to two three-month extensions), if a governmental order prohibits the transaction, or by mutual consent.
- Conditions Precedent: Includes expiration of the Hart-Scott-Rodino waiting period, accuracy of representations, and absence of a material adverse effect on DMG.
- Risks: Risks include failure to obtain regulatory approvals, disruption to business operations, and uncertainties regarding the ability to execute stock repurchases as planned.
Investor Verification Checklist
- Verify the status of regulatory approvals (Hart-Scott-Rodino and others) required for the closing.
- Confirm the final closing date and whether any extensions to the June 4, 2018 deadline are exercised.
- Monitor the actual execution of the planned stock repurchases and debt repayments following the transaction close.
- Review the full Equity Purchase Agreement (Exhibit 10.1) for specific representations, warranties, and indemnification obligations.
- Assess the impact of the non-compete and non-solicitation clauses on DaVita's future strategic options in the medical group space.